Wall Street: GLP-1 com­peti­tors’ pain is Eli Lil­ly’s gain

Eli Lil­ly’s stock con­tin­ued its wild ride Wednes­day af­ter lack­lus­ter da­ta from Am­gen’s po­ten­tial GLP-1 com­peti­tor fur­ther demon­strat­ed tirzepatide’s ad­van­tage.

On Wednes­day, Lil­ly shares …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER